US$ 22.72
tirzepatide and heart disease Bridging the gap between GLP1-receptor agonists cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Tirzepatide and Cardiovascular Outcomes: A
Description
Do not adjust your dose without talking to your prescribing healthcare provider

Generics match innovator safety due to bioequivalence
Manage constipation with fluids, fiber-rich foods like vegetables, berries, and oatmeal, and light activity

Check with your clinician before using large volumes of fluids if you have heart or kidney disease

Seek urgent medical attention (call 999 or attend A&E) if you experience: Signs of gastrointestinal bleeding : black, tarry stools (melaena), vomiting blood or material resembling coffee grounds, severe abdominal pain, or feeling faint and dizzy Severe allergic reactions : difficulty breathing, facial or throat swelling, or widespread rash Chest pain or signs of heart attack or stroke : sudden severe headache, weakness on one side of the body, or slurred speech Severe dehydration : inability to keep fluids down, reduced urination, confusion, or rapid heartbeat Severe, persistent abdominal pain (often radiating to the back) with vomiting stop taking Wegovy and seek urgent assessment (possible pancreatitis) Contact your GP, NHS 111, or healthcare provider within 24 hours if you develop: Persistent or worsening nausea and vomiting that prevents adequate nutrition or hydration New or worsening abdominal pain that is severe or different from typical Wegovy side effects Signs of kidney problems: reduced urine output, swelling of ankles or legs, or unexplained fatigue Unexplained bruising or bleeding Symptoms of anaemia: unusual tiredness, pale skin, or shortness of breath Right upper abdominal pain, fever, or yellowing of the skin or eyes (possible gallbladder disease) Arrange a routine appointment to discuss your medication combination if you experience persistent dyspepsia, require naproxen for more than a few days, or have concerns about side effects

GLP-1s on track to take drug sales throne from PD-1 inhibitors Fortune, September 5, 2023